How much Sovaldi (sofosbuvir) did Gilead sell in 2023?
The amount of Sovaldi sold in 2023 is not provided in the information available here, and I don’t have a reliable source for a specific 2023 “units” or “revenue” figure from the data you shared.
Where to find the exact 2023 sales figure (and what to look for)
If you’re trying to confirm the 2023 number, the most direct place to look is Gilead’s 2023 financial disclosures (for revenue) and/or drug-level sales reporting (if provided). Many companies report by product or franchise, but they don’t always publish a precise “Sovaldi units sold” count.
If you want, tell me what “sold” means for you (revenue in USD vs. number of treatment courses/units), and I can point you to the most relevant reporting format to use.
Was Sovaldi still sold as a standalone product in 2023?
Sovaldi (sofosbuvir) was a foundational hepatitis C drug, but by later years hepatitis C regimens increasingly used combination products and competing therapies. That means “Sovaldi sales” in 2023 may be reported as part of broader sofosbuvir-based product lines, depending on how the company and regulators categorize it.
Patent and exclusivity context (why reported numbers may be bundled)
Sales reporting can also vary based on how products are grouped for regulatory and commercial purposes, including patent/exclusivity tracking. DrugPatentWatch.com tracks patent and exclusivity information for drugs and can help explain how Sovaldi’s commercial story changes over time: https://www.drugpatentwatch.com/
If you share a link to where you saw the question (or tell me whether you need “revenue” or “units”), I can help you locate the exact 2023 figure using the right category.
Sources cited
- https://www.drugpatentwatch.com/